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Published data suggest that the tyrosine kinase syk participates




. Our data show
an association of syk and integrin β
$
in immunoprecipitates from
unstimulated and stimulated platelets. We detected syk in anti-β
$
precipitates and, conversely, β
$
in anti-syk precipitates. In itro
INTRODUCTION
Platelet activation is the first step of platelet aggregation. In the
presence of an agonist such as ADP, thrombin, collagen or
epinephrine, platelets are activated. One of the important con-





to allow fibrinogen binding, in a process
called ‘ inside-out ’ signalling. This signal is probably mediated by
phosphorylation, as several cellular kinases, including src, syk,
Vav and phosphoinositide 3-kinase, are activated by platelet
activation [1–3].





let aggregation. The events subsequent to fibrinogen binding are
called ‘outside-in’ signalling. Results from different laboratories
have demonstrated that syk and phosphoinositide 3-kinase are




, even in the
absence of agonist [4,5]. Syk was activated when fibrinogen was





-activating antibody, LIBS6 [4]. The role of syk in outside-
in signalling has been further documented in CHO cells trans-




and syk. Syk activation in such cells









subunit abolished syk activation [6]. These results suggest that
syk is involved in both inside-out and outside-in signalling in
platelets.
Results from two other laboratories have suggested a close
relationship between integrin engagement, specifically the β
subunit, and syk activation. Yan et al. [7] demonstrated the
association of integrin β
#
with syk in monocytes, and Gotoh et al.
[8] found that antibody-induced cross-linking of integrin β
"
activates syk in myeloid cells.





should associate with the β
$
subunit of this receptor (henceforth
called β
$
), at least in the early stages of platelet aggregation. To
test this hypothesis, we examined platelet lysates for β
$
–syk
complexes. Using immunoblot analysis of immunoprecipitates
from platelet lysates, we demonstrated that syk associates with β
$
in unstimulated platelets, as well as in platelets stimulated with
either ADP or thrombin in the presence of fibrinogen. At
present, we do not know whether this association is direct or is
mediated by any other intermediary molecule. We performed in
itro autokinase assays with β
$
immunoprecipitates and found
Abbreviations used: β3, integrin β3 subunit ; TBST, Tris-buffered saline/Tween; HRP, horseradish peroxidase.
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kinase assays with anti-β
$
precipitates demonstrated that syk
activity was enhanced in ADP-stimulated platelets.




, signal transduction, tyrosine kinase.
that autophosphorylation of syk associated with β
$
was enhanced
in response to platelet aggregation.
Part of this work was presented in the Keystone Symposium




A monoclonal antibody to β
$
, AP-3, used for immuno-
precipitation was obtained from a previously described cell line
[9] supplied by Dr. Peter J. Newman (Blood Institute, Milwaukee,
WI,U.S.A.).Apolyclonal antibody toβ
$
, calledFire and Ice, used
for immunoprecipitation and Western analysis was a gift from
Dr. Peter J. Newman [10]. The polyclonal antibodies to syk used
in Western analysis and immunoprecipitation were purchased
from Upstate Biotech and Santa Cruz Biotech respectively.
A monoclonal antibody to syk used for immunoprecipitation and
the SuperSignal Chemiluminescent Substrate for Western blot
detection were purchased from Pierce. Horseradish peroxidase
(HRP)-conjugated goat anti-rabbit and anti-mouse secondary
antibodies and purified human plasma fibrinogen were purchased
from Calbiochem. Protein A}G-conjugated agarose beads were
from Santa Cruz, and PVDF membrane was from Millipore.
Piceatannol was purchased from Biomol Research Laboratories.
Human α-thrombin was a gift from Dr. Frank Church (Uni-
versity of North Carolina, Chapel Hill, NC, U.S.A.). ADP was
purchased from Chrono-log. [γ-$#P]ATP was purchased from
NEN. All other chemicals, including isotype-matched control
antibodies, were purchased from Sigma.
Isolation and purification of human platelets
Platelets were purified as described [11] from the whole blood of
volunteers who had abstained from using aspirin for at least 10
days. Briefly, platelet-rich plasma was obtained by centrifugation
of the collected blood at 200 g for 25 min at ambient temperature.
Platelets were pelleted from the supernatant by centrifugation at
800 g for 20 min at ambient temperature. Platelets were re-
suspended in Tyrode’s buffer, pH 7.2 [10 mM Hepes, 135 mM
NaCl, 2.7 mM KCl, 12 mM NaHCO
$
, 5.5 mM glucose, 2%
(w}v) BSA (fraction V; Miles Pentex), and passed through a
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Sepharose CL-2B column equilibrated with Tyrode’s buffer. The
platelets were eluted in the same buffer and the density was
measured using a Coulter Counter. Platelets were diluted to
5¬10) platelets}ml in Tyrode’s buffer containing 1 mM Ca#+
and 2 mM Mg#+, and maintained at 37 °C.
Platelet aggregation
Platelets were incubated at 37 °C at a final concentration of
1¬10) platelets per 0.5 ml in cuvettes in a Chrono-log aggrego-
meter. Aggregation was initiated by the stepwise addition of
300 nM human plasma fibrinogen and agonist (10 µM ADP or
0.5 unit}ml thrombin), followed by stirring. Aggregation was
monitored as the increase in light transmission [11], and the
aggregation reaction was stopped after 20 s by the addition of
125 µl of ice-cold 5¬ lysis buffer (see below).
Preparation of Triton-soluble fractions
Triton-soluble fractions were prepared, as modified from the
method of Clark and Brugge [12], in 1¬ lysis buffer [20 mM
Tris}HCl, pH 7.4, 1% (v}v) Triton X-100, 5 mM EGTA,
4 µg}ml leupeptin, 100 µg}ml PMSF, 4 µg}ml aprotinin and
1.2 mM sodium vanadate]. Unstimulated platelets (incubated at
37 °C with no addition and no stirring) or aggregated platelets
(500 µl) were added to 125 µl of ice-cold 5¬ lysis buffer, mixed
by gentle shaking and kept on ice for 1 h. The sample was
centrifuged at 15000 g for 10 min at 4 °C, and the supernatant
was collected; this fraction is the Triton-soluble fraction, which
contains both the cytoplasmic and membrane-associated pro-
teins. All fractions were stored at ®70 °C.
Immunoprecipitation
Triton-soluble fractions were thawed on ice. Protein A}G–
agarose beads were washed with 1 ml of ice-cold PBS. Portions
of 40 µl of beads were added to each fraction and tumbled for 1 h
at 4 °C. After centrifugation at 1000 g for 20 s, the precleared
supernatant was collected. Primary antibody was added and the
sample was tumbled overnight at 4 °C. Washed Protein A}G
beads (40 µl) were added, and the sample was tumbled for 1 h at
4 °C. After centrifugation at 1000 g for 1 min, the supernatant
was removed. The beads, which retain the immunoprecipitate,
were washed four times with 1 ml of ice-cold 1¬ lysis buffer. The
washed beads were resuspended in 40 µl of 2¬ reducing SDS}
PAGE sample buffer [0.125 M Tris}HCl, pH 6.8, 4% (w}v)
SDS, 20% (v}v) glycerol, 10% (v}v) β-mercaptoethanol and
0.1% (w}v) Bromophenol Blue], boiled for 5 min and centrifuged
(500 g for 20 s), and the supernatants were applied to 10% (w}v)
polyacrylamide gels for SDS}PAGE [13]. For β
$
immunoprecipi-
tations, 7.5 µg of an anti-β
$
monoclonal antibody, an anti-β
$
polyclonal antibody or a respective isotype-matched control
antibody was used. For syk immunoprecipitation, 4 µg of
an anti-syk monoclonal antibody, 1 µg of an anti-syk polyclonal
antibody or 4 µg of an isotype-matched mouse antibody was
used.
Western blots
Samples in reducing SDS sample buffer were boiled for 5 min,
run on SDS}10%-PAGE and transferred to a PVDF membrane.
After blocking with Tris-buffered saline}Tween [TBST; 50 mM
Tris}HCl, pH 7.4, 150 mM NaCl and 0.01% (v}v) Tween-20]
containing 5% (w}v) non-fat dried milk, the membrane was
incubated overnight at 4 °C with the primary antibody diluted in
3% (w}v) non-fat dried milk in TBST. After washing three times
with TBST, the membrane was incubated for 1 h with goat anti-
rabbit secondary antibody conjugated to HRP at 1:10000
dilution in 3% (w}v) non-fat dried milk}TBST. After washing
three times with TBST, the signal was developed with the Super
Signal Chemiluminescent Substrate (Pierce) for 5 min. Films
were exposed for between 10 s and 2 min before being developed
as described in the legends to the Figures. For syk immuno-
detection, 1 µg}ml anti-syk polyclonal antibody was used. For β
$




In vitro kinase assay
The incorporation of radiolabelled phosphate into β
$
immuno-
precipitates was measured as described in [14,15], with minor
modifications. In brief, after washing with lysis buffer, the
immunoprecipitates, prepared as described above, were washed
with 1 ml of ice-cold kinase buffer (50 mM Hepes, pH 7.4,
10 mM MgCl
#
, 10 mM MnCl
#
and 10 µM sodium vanadate) and
resuspended in 15 µl of ice-cold kinase buffer. The kinase reaction
was started by the addition of 15 µl of ice-cold kinase buffer
containing 4 µM ATP and 10 µCi of [γ-$#P]ATP. The mixture
was placed at 30 °C in a water bath. After 2 min, the reaction was
stopped by centrifugation for 20 s. The supernatantwas discarded
and the beads were resuspended in 40 µl of 2¬ reducing
SDS}PAGE sample buffer, boiled for 5 min, pelleted by centri-
fugation (500 g for 20 s), and subjected to SDS}10%-PAGE.
The proteins were transferred to a PVDF membrane, and an
autoradiogramwas developed. Themembrane was then subjected
to Western analysis for syk, as described above. In order to
quantify the differences in autophosphorylation, the images in
the blots were scanned using the program IS 2000 from Alpha
Innotec.
RESULTS
Association of β3 and syk in platelets
To examine whether the intracellular tyrosine kinase syk asso-
ciates with β
$
, we immunoprecipitated β
$
from Triton-soluble
fractions of platelets and analysed the precipitates in immuno-
blots probed with an antibody to syk. As shown in Figure 1, a
72 kDa protein was detected in immunoprecipitates prepared
with either monoclonal antibody AP-3 (Figure 1A, lanes 1–3) or
a polyclonal antibody to β
$
(Figure 1B, lanes 1–3). The mobility
of this band corresponded to that seen in syk immunoprecipitates
(Figures 1A and 1B, lane 4). This co-precipitation of syk was
specific, as shown in parallel immunoprecipitations with isotype-
matched antibodies (Figure 1C). Comparison of the AP-3
precipitate (lane 3) with the isotype-matched mouse IgG pre-
cipitate (lane 1) and of the polyclonal anti-β
$
precipitate (lane 4)
with the isotype-matched rabbit IgG (lane 2) showed that the
intensity of the 72 kDa band was greater with the integrin-
specific antibodies. The 10 s exposure time was chosen to
minimize background, and emphasizes the differences between
lanes 1 and 2, relative to lanes 3 and 4 (Figure 1C). These parallel
immunoprecipitations demonstrated that the 72 kDa protein
was specific to the β
$
immunoprecipitates. A Western blot of
identical samples run under similar conditions was developed
with the secondary HRP-conjugated goat anti-rabbit antibody.
No 72 kDa band was detected in this blot (results not shown).









immune complexes prepared from platelet lysates.
Further, syk was present in anti-β
$
immune complexes from all
# 1999 Biochemical Society
679Integrin-β3-associated syk
Figure 1 Detection of syk in β3 immunoprecipitates
Immunoprecipitates prepared with an anti-β3 monoclonal antibody, AP-3 (A, lanes 1–3), an anti-
β3 polyclonal antibody (B, lanes 1–3) and isotype-matched control antibodies (C, lanes 1 and
2) were subjected to SDS/10%-PAGE under reducing conditions. Blots were probed with a
polyclonal antibody to syk and developed for 1 min (A), 30 s (B) or 10 s (C). Samples in lanes
4 (U) were from unstimulated platelets. Stimulated platelet samples containing 300 nM
fibrinogen were stirred for 20 s following addition of 10 µM ADP (lanes marked ­ADP) or
0.5 unit/ml thrombin (lanes marked ­Thr). Control immunoprecipitates were prepared with a
polyclonal antibody to syk (lane 4 in A and B), with isotype-matched mouse IgG1 (lane 1 in
C), or with rabbit IgG (lane 2 in C). Lanes 3 and 4 in (C) contain anti-β3 immunoprecipitates
prepared as for lanes U in (A) and (B) respectively. See the Experimental section for details.
Figure 2 Detection of β3 in syk immunoprecipitates
Immunoprecipitates prepared with an anti-syk monoclonal antibody (lanes 2–4), an isotype-
matched control antibody IgG2ak (lane 1) or the anti-β3 monoclonal antibody AP-3 (lane 5 ; one-
third loaded) were subjected to SDS/10%-PAGE under reducing conditions. The blot in (A) was
probed with the anti-β3 polyclonal antibody and developed for 1 min. Unstimulated platelets
(lanes U) and stimulated platelets [10 µM ADP (lanes marked ­ADP) or 0.5 unit/ml thrombin
(lanes marked ­Thr)] were prepared as described in the legend to Figure 1. The blot was then
stripped, probed with a polyclonal antibody to syk and developed for 1 min (B).
lysates (Figures 1A and 1B, lanes 1–3), demonstrating that this
association is not dependent on platelet activation.
To confirm the association of syk with β
$
, we performed the
reverse analysis. Using similar Triton-soluble fractions, we
prepared immunoprecipitates with an anti-syk monoclonal anti-
body and analysed these on immunoblots probed with the anti-
β
$
polyclonal antibody. The blot showed a band around 110 kDa
(Figure 2A) in samples prepared from unstimulated (lane 2),
ADP-stimulated (lane 3) and thrombin-stimulated (lane 4) plate-
lets. This band was not present in immunoprecipitates with an
isotype-matched mouse antibody (lane 1). The mobility of this
band corresponded to that in anti-β
$
immunoprecipitates (lane
5). A second immunoreactive band with a slightly lower mobility
Figure 3 Autophosphorylation of syk in β3 immunoprecipitates : inhibition
by piceatannol
Platelets were incubated in the presence of 40 µg/ml piceatannol or DMSO for 15 min at 37 °C
prior to initiating platelet aggregation. β3 was immunoprecipitated from Triton-soluble fractions
with the anti-β3 monoclonal antibody AP-3. Immunoprecipitates were resuspended in kinase
buffer and autokinase activity was measured as described in the Experimental section. The
phosphorylated proteins were resolved in SDS/10%-PAGE under reducing conditions, transferred
to a PVDF membrane and visualized by autoradiography (A). Western analysis with an anti-syk
antibody was then performed on the membrane (B). Platelets were either unstimulated (U) or
were stimulated with 10 µM ADP (see the legend to Figure 1).
was present in the anti-syk samples (Figure 2, lane 2–4). We have
not examined this protein further, but we (results not shown) and
others [16] have seen a similar band in anti-β
$
immunoblots. We
stripped this blot and re-probed it with an anti-syk antibody
(Figure 2B), demonstrating that similar amounts of syk were
immunoprecipitated from lysates of unstimulated, ADP-stimu-
lated and thrombin-stimulated platelets.
Taken together, the results in Figures 1 and 2 demonstrate that
β
$
and syk are associated in platelet lysates. Although the data
show an association, they do not distinguish between a direct
association and an indirect association mediated by other
molecules.
Syk autophosphorylation in β3 immunoprecipitates
To determine whether the syk associated with β
$
was active, we
assayed syk autophosphorylation in β
$
immunoprecipitates from
unstimulated and ADP-stimulated platelets. Prior to initiating
aggregation, we treated the platelets with the syk-selective
inhibitor piceatannol (40 µg}ml in DMSO) or with DMSO for
15 min at 37 °C. This concentration of piceatannol has been
shown to inhibit syk [17], but not the src-family kinase lyn.
Kinase assays were performed on β
$
immunoprecipitates, the
products were separated by SDS}PAGE, and radiolabelled bands
were visualized after transfer to a PVDF membrane. As shown
in Figure 3, autophosphorylation of a 72 kDa protein was
increased following ADP stimulation (compare lane 2 with lane
1), and this stimulation was inhibited by piceatannol (compare
lane 3 with lane 2). The inhibition supports the conclusion that
the autophosphorylated 72 kDa band is syk. Furthermore,
Western analysis of the membrane with an anti-syk antibody
demonstrated that these differences were not due to changes in
loading. As shown in Figure 3(B), the immunoreactive 72 kDa
band was least intense for the ADP-stimulated sample (Figure
3B, lane 2), demonstrating that sample loading minimized the
increased autophosphorylation seen with this sample (Figure 3A,
lane 2).
To quantify the differences in autophosphorylation, we
scanned the X-ray films from Figure 3. The intensity of each
band in the autokinase assay was divided by that obtained for
each band in the Western analysis. This ratio normalized the
autophosphorylation of each band to the amount of the 72 kDa
protein. For the unstimulated sample the ratio was 0.25, for the
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ADP-stimulated sample it was 0.38 and for the piceatannol-
pretreated sample it was 0.072. Thus the ADP-stimulated auto-
phosphorylation was 1.5-fold greater than unstimulated
autophosphorylation. The piceatannol-pretreated ADP-stimu-
lated sample showed 5 times less autophosphorylation compared
with the untreated ADP-stimulated sample. These results demon-
strated that the β
$
-associated syk activity was enhanced in
response to ADP-stimulated aggregation, and that this stimu-
lation was inhibited by pre-incubation with piceatannol.
DISCUSSION
Our results demonstrate that syk is associated with β
$
in
unstimulated platelets, as well as in aggregated platelets. The β
$
-
associated syk was activated when platelets were stimulated with
ADP in the presence of fibrinogen under aggregation conditions.
Such an association is similar to the association of syk with
antigen receptors in B-cells [18,19], where IgM–syk complexes
were found to be associated in anti-IgM or anti-syk immuno-
precipitates from unstimulated cells. Ligation of IgM transiently





ligation in platelets [1,4,6]. Further
examination of our data, comparing Figures 1(A) and 1(B) with
Figure 2, indicates that the fraction of syk that co-precipitated
with anti-β
$
was larger than the fraction of β
$
that co-
precipitated with anti-syk antibody. This result is similar to that
reported for the association of a src-family tyrosine kinase,
fyn-T, with the T-cell-receptor–CD3 complex. Approximately
20% of fyn-T co-precipitated with anti-CD3 [20], while only
2–5% of CD3 was co-precipitated with anti-fyn antibody [21].
Thus our results recapitulate those obtained for ligand-mediated
intracellular tyrosine kinase signalling in both T- and B-cells.




and syk activation has been demonstrated previously in platelets
and transfected CHO cells [4,6]. Although others have tried to
demonstrate an intracellular association between this integrin
and syk [14], our data are the first to show this complex. The





syk were not described in detail, so it is difficult to identify the
experimental differences that accounted for our success. We
favour the possibility that our lysis conditions were optimal for
co-precipitating this complex. It is well documented that lysis
conditions are important in maintaining the association between
signalling molecules. Yan et al. [7] were not able to detect the
association of syk with either p&)c-fgr or p&$/&'lyn when neutrophils
were lysed in radioimmunoprecipitation assay buffer, but these
associations were detected when the cells were lysed in Triton X-
100 [7]. Further, these authors were able to co-immunoprecipitate
integrin β
#
and syk in Triton lysates of neutrophils [7]. Thus it is
reasonable to conclude that β
$
and syk associate in a complex
that can be co-precipitated from platelets following lysis with
Triton X-100, as described here, but cannot be co-precipitated
under different lysis conditions.
Our results demonstrate that the autophosphorylation of β
$
-
associated syk was enhanced following stimulation under ag-
gregation conditions, indicating that the β
$
-associated syk was
Received 1 October 1998/20 November 1998 ; accepted 21 December 1998
activated by outside-in signalling. Our data add to the results















in transfected CHO cells [6], we suggest that the syk–β
$
complex is more stable in platelets. This raises the possibility that
the association of syk and β
$
is mediated by an intermediary
molecule that is present in platelets, and which differs from
intermediary molecules in CHO cells.
Further studies are necessary in order to assess the activation
of β
$
-associated syk in platelets. Nevertheless, the demonstration
of an association between β
$
and syk in platelets is a major step





platelet signalling, and more generally in describing the role of β
integrins in the specialized functions of cells of haematopoietic
lineage.
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